|
| Press Releases |
|
 |
|
| Wednesday, April 15, 2015 |
|
|
Nanobiotix: 2014 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its audited consolidated results for the fiscal year ended December 31, 2014. more info >> |
|
| Tuesday, February 24, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Monday, February 23, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Friday, February 20, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Thursday, October 16, 2014 |
|
|
Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, October 8, 2014 |
|
|
PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205- PEA PME eligible), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer today announces the update of the development plan for NBTXR3. more info >> |
|
| Monday, June 2, 2014 |
|
|
Nanobiotix Presents Successful Phase I Results for Its Lead Nanomedicine Product NBTXR3 at ASCO |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented today at the American Society of Clinical Oncology annual meeting. more info >> |
|
| Tuesday, February 11, 2014 |
|
|
NANOBIOTIX sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its development plan for the CE marking of NBTXR3, the first product from the NanoXray pipeline. more info >> |
|
| Friday, December 6, 2013 |
|
|
NANOBIOTIX Strengthens its NanoXray Pipeline with the Launch of NBTX-TOPO Development, the First Nanotherapeutic with Embedded Radar |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today, in accordance with its plans, the selection of its new product, NBTX-TOPO, in view of its preclinical development. more info >> |
|
| Monday, September 23, 2013 |
|
|
NANOBIOTIX Strengthens Its Management Team |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the strengthening of its management team to support the company's growth within its business strategy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR(R)
Nov 24, 2024 23:54 HKT/SGT
|
|
|
New Progress in the Merger of Guotai Junan and Haitong Securities
Nov 24, 2024 18:14 HKT/SGT
|
|
|
國泰君安、海通證券合併新進展 協同效應位居行業第一
Nov 24, 2024 18:10 HKT/SGT
|
|
|
国泰君安、海通证券合并新进展 协同效应位居行业第一
Nov 24, 2024 18:01 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. 推出清潔解決方案 從工業現場到公共設施營造宜人的室內環境
Nov 24, 2024 08:00 HKT/SGT
|
|
|
Daeshin MC Co., Ltd.推出清洁解决方案 从工业现场到公共设施营造宜人的室内环境
Nov 24, 2024 08:00 HKT/SGT
|
|
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
达丰设备服务有限公司 公布2024/25中期业绩
Nov 22, 2024 19:35 HKT/SGT
|
|
|
達豐設備服務有限公司 公佈2024/25中期業績
Nov 22, 2024 19:18 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
